NRXP · NRX Pharmaceuticals, Inc. · Fails to Deliver
$3.45
-0.02 (-0.58%)
At close · Sep 9
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$145.91M
Shares
43.30M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-08-14 | 6,377 | $3.34 | $21,299 |
| 2026-08-13 | 25 | $3.36 | $84 |
| 2026-08-12 | 20,165 | $3.40 | $68,561 |
| 2026-08-11 | 65,023 | $3.35 | $217,827 |
| 2026-08-10 | 26,724 | $3.58 | $95,672 |
| 2026-08-04 | 373 | $3.24 | $1,209 |
| 2026-08-03 | 20,491 | $3.15 | $64,547 |
| 2026-07-29 | 24,581 | $3.54 | $87,017 |
| 2026-07-27 | 18,739 | $3.75 | $70,271 |
| 2026-07-24 | 2,527 | $4.11 | $10,386 |
| 2026-07-23 | 7,672 | $4.48 | $34,371 |
| 2026-07-17 | 17,152 | $4.24 | $72,724 |
| 2026-07-16 | 597 | $4.46 | $2,663 |
| 2026-07-14 | 27,376 | $4.15 | $113,610 |
| 2026-07-10 | 20,332 | $4.11 | $83,565 |
| 2026-07-08 | 8,996 | $4.16 | $37,423 |
| 2026-07-07 | 35 | $3.95 | $138 |
| 2026-07-06 | 200 | $3.87 | $774 |
| 2026-07-02 | 996 | $3.86 | $3,845 |
| 2026-07-01 | 2,930 | $4.09 | $11,984 |
| 2026-06-30 | 13,003 | $4.00 | $52,012 |
| 2026-06-29 | 4,258 | $3.73 | $15,882 |
| 2026-06-26 | 3,392 | $3.56 | $12,076 |
| 2026-06-25 | 6,230 | $3.56 | $22,179 |
| 2026-06-24 | 2,796 | $3.76 | $10,513 |
| 2026-06-23 | 25,999 | $3.90 | $101,396 |
| 2026-06-18 | 5,081 | $3.98 | $20,222 |
| 2026-06-16 | 5,923 | $4.08 | $24,166 |
| 2026-06-15 | 9,416 | $3.84 | $36,157 |
| 2026-06-10 | 448 | $3.87 | $1,734 |
Showing 1–30 of 30 settlements
Key facts
CIK
1719406
CUSIP
629444209
13F (30d)
33 filings
33 filers
Visit website
Investor relations